SCHEMBL7040893

SCHEMBL7040893

Cc1cc(-n2nc(OC(C)C)oc2=O)ccc1NC(=O)OCc1ccccc1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 2/20 0.83
FAAH O00519 1/20 0.83
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
BCHE P06276 1/20 0.45
LIPC P11150 1/20 0.45
ACHE P22303 1/20 0.45
LIPE Q05469 1/20 0.45
MAOB P27338 1/20 0.43
OPRK1 P41145 1/20 0.42
F10 P00742 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
MAOA P21397 1/20 0.41
ATM Q13315 1/20 0.41
CARM1 Q86X55 1/20 0.40
ELANE P08246 1/20 0.39
MAP3K5 Q99683 1/20 0.39
CASP3 P42574 1/20 0.39
MAPT P10636 1/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29499689 0.91 MGLL (1.00) MGLLFAAHNPC1RAB9ABCHE
SCHEMBL7042914 0.91 MGLL (1.00) MGLLFAAHNPC1RAB9ABCHE
SCHEMBL7046374 0.89 MGLL (0.83) MGLLFAAHNPC1RAB9ABCHE
SCHEMBL7039924 0.88 MGLL (0.81) MGLLFAAHNPC1RAB9ABCHE
SCHEMBL7039930 0.84 FAAH (0.59) MGLLFAAHNPC1RAB9ALIPC
SCHEMBL7043936 0.81 MGLL (0.82) MGLLFAAHNPC1RAB9ALIPC
SCHEMBL7043147 0.80 MGLL (0.81) MGLLFAAHNPC1RAB9ABCHE
SCHEMBL7046148 0.79 MGLL (0.78) MGLLFAAHLIPCLIPESMN1; SMN2
SCHEMBL7046095 0.76 MGLL (0.74) MGLLFAAHBCHELIPCACHE
SCHEMBL7045850 0.76 MGLL (0.72) MGLLFAAHNPC1RAB9ABCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030236288-A1 Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase AVENTIS PHARMA DEUTSCHLAND GMBH 2003-12-25 US disclosed
US-6369088-B2 ANTIDIABETIC AGENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-09 US disclosed
US-20010031772-A1 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031772-A1 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals CNR1, PTGER1, CNR2 MGLL 1542/4885FAAH 46/4885NPC1 622/4885
US-20030236288-A1 Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase PNLIP, CEL, LIPE MGLL 10/4885FAAH 142/4885NPC1 730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.